When the Coverage Doesn’t Cover What You Need
Medicaid pharmacy carve-outs – a policy mechanism that separates drug benefits from managed care plans into standalone programs – were originally designed to give states more control over pharmacy spending. For patients who depend on specialty medications to manage conditions like multiple sclerosis, HIV, rheumatoid arthritis, or rare genetic disorders, that administrative reshuffling has become a serious barrier to care.
How Carve-Outs Create Gaps in the System
When a state carves out pharmacy benefits, it means a Medicaid managed care organization (MCO) is no longer responsible for covering prescription drugs. Instead, the state runs drug coverage through a separate fee-for-service system or contracts with a pharmacy benefit manager (PBM) directly. On paper, this can reduce costs through centralized negotiating power. In practice, it splits the coordination of a patient’s care across two separate systems that rarely communicate well.
The coordination failure is most painful for specialty drug patients. A managed care plan covering a patient’s rheumatology appointments operates under one set of formularies and prior authorization requirements. The carved-out pharmacy program operates under another. When a rheumatologist prescribes a biologic drug, the approval process now involves both entities – and the patient sits in the middle, often waiting weeks for decisions that should take days. Specialty drugs, by definition, require careful monitoring, dose adjustments, and clinical follow-up. A system that separates the prescriber’s plan from the pharmacy program undermines all of that.
States that have adopted carve-outs often point to rebate revenue as the driving justification. Under federal law, Medicaid programs receive mandatory rebates from drug manufacturers. When drugs flow through a fee-for-service carve-out rather than through MCO formularies, states can capture a larger share of those rebates directly. That math works reasonably well for generic drugs and common brand-name medications. It works far less well for specialty drugs, where formulary placement, step therapy requirements, and prior authorization delays introduce costs that never appear in a rebate spreadsheet – costs borne entirely by patients and providers.
Prior authorization is where the patient experience breaks down most visibly. Specialty drugs almost always require prior authorization under any Medicaid structure, but carve-outs add an additional layer of administrative complexity. A managed care plan might approve a patient for a biologic therapy based on clinical records it already holds. The carved-out PBM, operating independently, may require the same documentation all over again – or apply different clinical criteria entirely. For a patient managing a condition like Crohn’s disease or lupus nephritis, a two-week delay in specialty drug access is not an inconvenience. It is a medical event.
The Specialty Drug Access Squeeze in Real Terms
Specialty medications are not a niche concern within Medicaid. They account for a disproportionate share of total drug spending precisely because the conditions they treat are serious, chronic, and high-cost to manage when uncontrolled. When a patient with HIV misses doses of antiretroviral therapy because their specialty drugs are caught in a formulary dispute between their MCO and the carved-out program, the downstream cost – hospitalizations, emergency interventions, disease progression – far exceeds the rebate savings that motivated the carve-out in the first place.
The formulary misalignment problem compounds this. Under a fully integrated MCO model, a health plan has financial incentive to ensure specialty drugs are accessible – because the plan is also on the hook for the medical costs of poorly managed chronic disease. Under a carve-out, that incentive disappears. The MCO no longer controls pharmacy, so it has limited leverage over drug access decisions. The PBM running the carved-out benefit is optimizing for drug spend in isolation, without visibility into the medical cost consequences of delayed or denied specialty therapy. The two systems are solving different problems, and the patient bears the gap between them.
Step therapy – the requirement that a patient try and fail on a cheaper medication before accessing the prescribed specialty drug – is applied more aggressively in carved-out systems, where pharmacy cost control is the primary mandate. For a patient whose specialist has already determined, based on clinical evidence and prior treatment history, that a specific biologic is appropriate, step therapy requirements add months to the access timeline. Some patients cycle through cheaper drugs that were never clinically indicated for them before they finally reach the medication their physician originally recommended. That process is not only inefficient – it is medically harmful for conditions where early, targeted treatment produces meaningfully better outcomes.
Specialty pharmacies add another layer of friction. Many specialty drugs require cold-chain handling, patient education, and ongoing clinical monitoring that only specialty pharmacies can provide. Carved-out Medicaid programs sometimes use narrow pharmacy networks that exclude specific specialty pharmacies – particularly those embedded in health systems or hospital clinics that serve high concentrations of Medicaid patients. When a patient cannot fill their specialty drug at the pharmacy attached to their treating hospital, they face additional logistics that many low-income patients simply cannot navigate. Transportation, work schedules, and limited health literacy all interact with these structural barriers in ways that quietly push patients out of treatment.
States that have moved to reintegrate pharmacy benefits back into managed care – or that never carved them out – offer a comparison point. Integrated models allow MCOs to build care management programs around specialty drug adherence, connect pharmacy data with medical records, and apply prior authorization criteria that reflect the clinical context of the patient’s full care plan. That integration does not eliminate all access problems, but it closes the coordination gap that carve-outs create by design.
What States Are Weighing Against What Patients Are Losing
The financial logic of carve-outs is not imaginary. States facing Medicaid budget pressure have real reasons to consolidate pharmacy purchasing and maximize rebate capture. Some states have built carve-out programs sophisticated enough to include care transition protocols and specialty drug exception processes that reduce – though do not eliminate – the access gaps. The policy question is whether those administrative gains are being traded against outcomes that Medicaid was designed to protect in the first place.
Low-income patients with serious chronic conditions are not a population with backup options. They cannot self-pay for a specialty drug that costs tens of thousands of dollars annually. They cannot easily switch to a private plan with better specialty drug access. When the Medicaid system creates administrative barriers between a patient and a medically necessary specialty medication, there is no safety net beneath the safety net. Several states are currently under scrutiny from federal Medicaid oversight for prior authorization practices that result in specialty drug denial rates significantly higher than their non-carved-out counterparts – which raises a direct question about whether carve-out structures, as currently implemented, are compatible with the federal requirement that Medicaid benefits be available with reasonable promptness.
